Systemic inflammatory biomarkers may be useful in the differential diagnosis of primary central nervous system lymphoma, high-grade glioma
MONDAY, April 18, 2022 (HealthDay News) — Systemic inflammatory biomarkers may aid in differentiating primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG), according to a study published online April 4 in CNS Oncology.
Tejpal Gupta, M.D., from the Homi Bhabha National Institute in Mumbai, India, and colleagues calculated systemic inflammatory indices from pretreatment complete blood counts and liver function tests and compared them against histopathology as a reference standard among 42 patients with PCNSL and 16 with HGG.
The researchers observed significant differences in the mean values for absolute lymphocyte count and prognostic nutritional index between PCNSL and HGG patients. For absolute lymphocyte count and prognostic nutritional index, the area under the receiver operating characteristic curve in the diagnosis of PCNSL was 0.70 and 0.72, respectively, indicating fair and acceptable diagnostic accuracy.
“This exploratory first-of-a kind study assessed the utility of systemic inflammatory biomarkers derived from routine blood investigations in a cohort of patients with suspected PCNSL to differentiate them reliably from HGG with similar morphologic imaging,” the authors write.
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer 
Estimated Glucose Disposal Rate Inversely Linked to Benign Prostatic Hyperplasia 
Machine Learning Model IDs Heart Failure With Reduced Ejection Fraction Using Routine Lab Indicators 
Addition of CAC to PREVENT-ASCVD Equations May Improve Predictive Utility in Certain Patients .jpg)
Warning Symptoms, Clinical History Can Predict Sudden Cardiac Arrest .jpg)
Micro-, Nanoplastics Detected More Often in Patients With STEMI 
AI Can Accurately Detect Left Ventricular Dysfunction From Electrocardiograms 
Differences in Cardiovascular Risk Factor Prevalence ID"d for South Asian Adults 
